Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors

Title:Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors

Volume: 21 Issue: 41

Author(s): M. Eugenia Cifuentes-Pagano, Daniel N. Meijles and Patrick J. Pagano

Affiliation:

Keywords: NADPH oxidase, Nox, inhibitors, peptides, small molecules, therapeutics.

Abstract: Oxidative stress-related diseases underlie many if not all of the major leading causes of death in United States and the Western World. Thus, enormous interest from both academia and pharmaceutical industry has been placed on the development of agents which attenuate oxidative stress. With that in mind, great efforts have been placed in the development of inhibitors of NADPH oxidase (Nox), the major enzymatic source of reactive oxygen species and oxidative stress in many cells and tissue. The regulation of a catalytically active Nox enzyme involves numerous protein-protein interactions which, in turn, afford numerous targets for inhibition of its activity. In this review, we will provide an updated overview of the available Nox inhibitors, both peptidic and small molecules, and discuss the body of data related to their possible mechanisms of action and specificity towards each of the various isoforms of Nox. Indeed, there have been some very notable successes. However, despite great commitment by many in the field, the need for efficacious and well-characterized, isoform-specific Nox inhibitors, essential for the treatment of major diseases as well as for delineating the contribution of a given Nox in physiological redox signalling, continues to grow.

Cite this article as:

Cifuentes-Pagano Eugenia M., Meijles N. Daniel and Pagano J. Patrick, Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors, Current Pharmaceutical Design 2015; 21 (41) . https://dx.doi.org/10.2174/1381612821666151029112013